|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial显示文摘AIM: To estimate if and to what extent long acting octreotide (LAR) improves survival and quality of life in patients with advanced hepatocellular carcinoma (HCC). METHODS: A total of 127 cirrhotics, stages A-B, due to chronic viral infections and with advanced HCC, were enrolled in the study. Scintigraphy with 111Indium labeled octreotide was performed in all cases. The patients with increased accumulation of radionuclear compound were randomized to receive either oral placebo only or octreotide/octreotide LAR only as follows: octreotide 0.5mg s.c. every 8 h for 6 wk, at the end of wk 4-8 octreotide LAR 20 mg i.m. and at the end of wk 12 and every 4 wk octreotide LAR 30mg i.m.. Follow-up was worked out monthly as well as the estimation of quality of life (QLQ-C30 questionnaire). Patients with negative somatostatin receptors (SSTR) detection were followed up in the same manner. RESULTS: Scintigraphy demonstrated SSTR in 61 patients. Thirty were randomized to receive only placebo and 31 only octreotide. A significantly higher survival time was observed for the octreotide group (49 ± 6 wk) as compared to the control group (28 ± 1 wk) and to the SSTR negative group (28 ± 2 wk), LR = 20.39, df = 2, P < 0.01. The octreotide group presented 68.5% lower hazard ratio [95% CI (47.4%-81.2%)]. During the f irst year, a 22%, 39% and 43% decrease in the QLQ-C30 score was observed in each group respectively.CONCLUSION: The proposed therapeutic approach has shown to improve the survival and quality of life in SSTR positive patients with advanced HCC. | D Dimitroulopoulos D Xinopoulos K Tsamakidis A Zisimopoulos E Andriotis D Panagiotakos A Fotopoulou C Chrysohoou A Bazinis D Daskalopoulou E Paraskevas | 2007 | World Journal of Gastroenterology2007，13，23： | 18 |
| 2 | Gestational diabetes and hypertensive disorders of pregnancy as vascular risk signals : an overview and grading of the evidence 显示文摘 | Nerenberg K Daskalopoulou SS Dasgupta K | 2014 | Can J Cardiol2014，30，7： | 1 |
| 3 | The 2012 Canadian hypertension education program recommendations for the management of hy- pertension: blood pressure measurement, diagnosis, assessment of risk, and therapy显示文摘 | DASKALOPOULOU S S KHAN N A QUINN R R | 2012 | Can J Cardiol2012，28，： | 1 |
| 4 | The combined effect of hypertension and smoking on arterial stiffness 显示文摘 | Scallan C Doonan R J Daskalopoulou SS | 2010 | Clin Exp Hypertens2010，32，： | 1 |
| 5 | Matrixmetalloproteinases and diabetic vascular complications 显示文摘 | Kadoglou N P Daskalopoulou S S Perrea D | 2005 | Angiology2005，56，2： | 1 |
| 6 | The 2015Canadian Hypertension Education Program recommendations for blood pressure measurement,diagnosis,assessment of risk,prevention,and treatment of hypertension显示文摘 | Daskalopoulou SS Rabi DM Zarnke KB | 2015 | Can J Cardiol2015，31，5： | 1 |
| 7 | Detection of early atherosclerosis using the ultrasound parameters of the intima-media thickness of the common carotid artery in families with familial combined hyperlipidaemia 显示文摘 | Daskalopoulou SS Daskalopoulos ME Mikhailidis DP | 2005 | Int Angiol2005，24，4： | 1 |
| 8 | The impact of serum uric acid on cardiovascular outcomes in the LIFE study显示文摘 | Daskalopoulou SS Athyros VG Elisaf M | 2004 | Kidney Int2004，66，： | 1 |
| 9 | Sex differences in acute coronary syndrome symptom presentation in young patients 显示文摘 | Khan NA Daskalopoulou SS Karp I | 2013 | JAMA Intern Med2013，173，20： | 1 |
| 10 | Carotid artery athemsclerosis: what is the evidence for drug action? 显示文摘 | Daskalopoulou SS Daskalopoulos ME Perrea D | 2007 | Curt Pharm Des2007，13，11： | 1 |
| 11 | The 2012 Cana- dian hypertension edueation program reeommendations for the management of hypertension : blood pressure measurement, diag- nosis, assessment of risk, and therapy 显示文摘 | Daskalopoulou SS Khan NA Quinn RR | 2012 | Can J Cardiol2012，28，3： | 1 |
| 12 | Sex- and gender-related risk factor burden in patients with premature acute coronary syndrome显示文摘 | Choi J Daskalopoulou SS Thanassoulis G | 2014 | Can J Cardiol2014，30，1： | 1 |
| 13 | The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice:position statement of a United Kingdom consensus panel显示文摘 | Mikhailidis DP Wierzbicki AS Daskalopoulou SS | 2005 | Curr Med Res Opin2005，2，： | 1 |
| 14 | Carotid artery athemsclerosis:what is the evidence for drug action显示文摘 | Daskalopoulou SS Daskalopoulos ME Perrea D | 2007 | Curr Pharm Des2007，13，11： | 1 |
| 15 | The 2015canadian hypertension education program recommendations for blood pressure measurement,diagnosis,assessment of risk,prevention,and treatment of hypertension显示文摘 | Daskalopoulou SS Rabi DM Zarnke KB | 2015 | Can J Cardiol2015，31，5： | 1 |
| 16 | Stroke : epidemiology, clinical picture, and risk factors-Part Ⅰ of Ⅲ 显示文摘 | Tegos TJ Kalodiki E Daskalopoulou SS | 2000 | Angiology2000，51，10： | 1 |
| 17 | Uric acid levels and vascular disease显示文摘 | S. S. Daskalopoulou V. G. Athyros M. Elisaf D. P. Mikhailidis | 2004 | Current Medical Research and Opinion?2004，，6： | 1 |
| 18 | Evaluation of argyrophilic nucleolar organiser regions (AgNORs) in multiple myeloma 显示文摘 | Papadhimitriou SI Daskalopoulou D Tsaftaridis P | 2000 | J Clin Pathol2000，53，6： | 1 |
| 19 | Low molecular weight heparins in the long-term treatment of venous thromboembolism显示文摘 | Liapis CD Daskalopoulos ME Daskalopoulou SE | 2002 | J Cardiovasc Surg2002，43，4： | 1 |
| 20 | A review of the lipid-related effects of fluvastatin 显示文摘 | Liberopoulos EN Daskalopoulou SS Mikhailidis DP | 2005 | Curr Med Res Opin2005，21，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员